Cargando…
Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies
Significant progress has been made in preventing severe COVID-19 disease through the development of vaccines. However, we still lack a validated baseline predictive biologic signature for the development of more severe disease in both outpatients and inpatients infected with SARS-CoV-2. The objectiv...
Autores principales: | Castro-Pearson, Sandra, Samorodnitsky, Sarah, Yang, Kaifeng, Lotfi-Emran, Sahar, Ingraham, Nicholas E., Bramante, Carolyn, Jones, Emma K., Greising, Sarah, Yu, Meng, Steffen, Brian, Svensson, Julia, Åhlberg, Eric, Österberg, Björn, Wacker, David, Guan, Weihua, Puskarich, Michael, Smed-Sörensen, Anna, Lusczek, Elizabeth, Safo, Sandra E., Tignanelli, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661735/ https://www.ncbi.nlm.nih.gov/pubmed/37985892 http://dx.doi.org/10.1038/s41598-023-46343-1 |
Ejemplares similares
-
Proteomic pathways associated with developing severe disease for patients with COVID-19: A biologic analysis of data from two multicenter randomized controlled trials encompassing 13 U.S. hospitals
por: Samorodnitsky, Sarah, et al.
Publicado: (2023) -
Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers
por: Yang, Kaifeng, et al.
Publicado: (2023) -
We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
por: Dutta, Nirjhar, et al.
Publicado: (2021) -
Immunomodulation in COVID-19
por: Ingraham, Nicholas E, et al.
Publicado: (2020) -
Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles
por: Lusczek, Elizabeth R., et al.
Publicado: (2021)